LATS2 and neoplasm: LATS2-mutated Y-MESO-27 cells were implanted into the mouse thoracic cavity and BIBR 1532 (2 mg/kg) was intraperitoneally administered twice-weekly after transplanting cells to investigate tumor growth and mouse survival (Fig. 6A).